DHR Stock Analysis: Danaher | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 153.595m USD | 12M Return: 8.3% | US2358511028 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 958M
EPS Trend: -44.8%
Qual. Beats: 2
Rev. Trend: -17.3%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Danaher Corporation (NYSE: DHR) is a U.S.-based diversified manufacturer operating in the professional, medical, research, and industrial sectors with primary markets in the United States, China, and other international regions. The company is structured around three segments-Biotechnology, Life Sciences, and Diagnostics-serving customers across biopharmaceutical production, scientific research, and clinical diagnostics. As a large-cap healthcare equipment company with a market capitalization of approximately $156 billion, Danaher operates in a sector where scale and recurring consumables revenue are key competitive advantages.
The Biotechnology segment supplies tools, consumables, and services that support the development and manufacturing of therapeutics, including cell culture media, chromatography resins, filtration technologies, aseptic fill-finish systems, and single-use bioprocessing hardware. This segment positions Danaher in the rapidly growing bioprocessing market, where demand is driven by the expanding pipeline of biologic drugs, monoclonal antibodies, and gene therapies produced by pharmaceutical and biotechnology firms.
The Life Sciences segment offers a broad portfolio of laboratory instruments, consumables, and reagents under well-known brands such as Beckman Coulter, Leica Microsystems, SCIEX, Pall, Phenomenex, IDT, Abcam, and Aldevron. Products include mass spectrometers, flow cytometry systems, genomic tools, microscopes, and custom nucleic acid products. This segment serves academic, government, and industrial research customers and benefits from ongoing investment in life sciences research and the genomics and precision medicine markets.
The Diagnostics segment provides clinical instruments, consumables, software, and services used by hospitals, physicians offices, and reference laboratories to diagnose disease and guide treatment decisions. The clinical diagnostics industry is characterized by high barriers to entry due to regulatory requirements, established installed bases, and the recurring nature of consumable test sales, which contribute to predictable revenue streams.
Danaher Corporation was originally incorporated in 1969 as Diversified Mortgage Investors, Inc. and adopted its current name in 1984. The company is headquartered in Washington, D.C., and has been publicly traded since 1979.
- China biotech demand weakness pressures Biotechnology segment growth
- Diagnostics margins expand on Cepheid test volume and pricing
- Aldevron and Abcam integration drives Life Sciences consumables revenue
| Net Income: 4.00b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.04 > 1.0 |
| NWC/Revenue: 21.01% < 20% (prev 17.52%; Δ 3.49% < -1%) |
| CFO/TA 0.07 > 3% & CFO 6.63b > Net Income 4.00b |
| Net Debt (23.5b) to EBITDA (7.58b): 3.10 < 3 |
| Current Ratio: 1.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (707.6m) vs 12m ago -1.60% < -2% |
| Gross Margin: 58.51% > 18% (prev 61.45%; Δ -2.94% > 0.5%) |
| Asset Turnover: 28.86% > 50% (prev 29.42%; Δ -0.56% > 0%) |
| Interest Coverage Ratio: 17.31 > 6 (EBIT TTM 5.05b / Interest Expense TTM 292.0m) |
| A: 0.06 (Total Current Assets 13.4b - Total Current Liabilities 8.11b) / Total Assets 92.4b |
| B: 0.52 (Retained Earnings 48.2b / Total Assets 92.4b) |
| C: 0.06 (EBIT TTM 5.05b / Avg Total Assets 87.0b) |
| D: 1.32 (Book Value of Equity 52.6b / Total Liabilities 39.8b) |
| Altman-Z'' = 3.85 = AA |
| DSRI: 0.84 (Receivables 3.96b/4.52b, Revenue 25.1b/24.0b) |
| GMI: 1.05 (GM 61.45% / 58.51%) |
| AQI: 0.99 (AQ_t 0.78 / AQ_t-1 0.79) |
| SGI: 1.05 (Revenue 25.1b / 24.0b) |
| TATA: -0.03 (NI 4.00b - CFO 6.63b) / TA 92.4b) |
| Beneish M = -3.09 (Cap -4..+1) = AA |
As of October 10, 2026, the stock is trading at USD 219.81 with a total of 3,934,188 shares traded. Over the past week, the price has changed by +2.69%, over one month by +7.49%, over three months by +12.36% and over the past year by +8.29%.
Current recommended Stop Loss: 205.40 (which is 6.6% or 2.2 ATR below the current price).
Danaher has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy DHR.
- StrongBuy: 17
- Buy: 5
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 239.5 | 9% |
P/E Trailing = 38.4666
P/E Forward = 23.8095
P/S = 6.1176
P/B = 2.9559
P/EG = 1.3236
Revenue TTM = 25.1b USD
EBIT TTM = 5.05b USD
EBITDA TTM = 7.58b USD
Long Term Debt = 25.1b USD (from longTermDebt, last quarter)
Short Term Debt = 1.41b USD (from shortTermDebt, last quarter)
Debt = 27.8b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.28b
Net Debt = 23.5b USD (calculated: Debt 27.8b - CCE 4.35b)
Enterprise Value = 177b USD (154b + Debt 27.8b - CCE 4.35b)
Interest Coverage Ratio = 17.31 (Ebit TTM 5.05b / Interest Expense TTM 292.0m)
EV/FCF = 32.40x (Enterprise Value 177b / FCF TTM 5.47b)
FCF Yield = 3.09% (FCF TTM 5.47b / Enterprise Value 177b)
FCF Margin = 21.77% (FCF TTM 5.47b / Revenue TTM 25.1b)
Net Margin = 15.95% (Net Income TTM 4.00b / Revenue TTM 25.1b)
Gross Margin = 58.51% ((Revenue TTM 25.1b - Cost of Revenue TTM 10.4b) / Revenue TTM)
Gross Margin QoQ = 57.64% (prev 60.34%)
Tobins Q-Ratio = 1.92 (Enterprise Value 177b / Total Assets 92.4b)
Interest Expense / Debt = 1.05% (Interest Expense 292.0m / Debt 27.8b)
Taxrate = 15.92% (758.0m / 4.76b)
NOPAT = 4.25b (EBIT 5.05b * (1 - 15.92%))
Current Ratio = 1.65 (Total Current Assets 13.4b / Total Current Liabilities 8.11b)
Debt / Equity = 0.53 (Debt 27.8b / totalStockholderEquity, last quarter 52.6b)
Debt / EBITDA = 3.10 (Net Debt 23.5b / EBITDA 7.58b)
Debt / FCF = 4.30 (Net Debt 23.5b / FCF TTM 5.47b)
Total Stockholder Equity = 52.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.60% (Net Income 4.00b / Total Assets 92.4b)
RoE = 7.66% (Net Income TTM 4.00b / Total Stockholder Equity 52.3b)
RoCE = 6.53% (EBIT 5.05b / Capital Employed (Equity 52.3b + L.T.Debt 25.1b))
RoIC = 5.03% (NOPAT 4.25b / Invested Capital 84.4b)
WACC = 6.37% (E(154b)/V(181b) * Re(7.36%) + D(27.8b)/V(181b) * Rd(1.05%) * (1-Tc(0.16)))
Discount Rate = 7.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.19 | Cagr: -2.47%
[DCF] Terminal Value 76.93% ; FCFF base≈5.22b ; Y1≈5.78b ; Y5≈7.45b
[DCF] Fair Price = 128.2 (EV 114b - Net Debt 23.5b = Equity 90.1b / Shares 703.0m; r=8.35% [WACC [floored]]; 5y FCF grow 12.42% → 2.50% )
EPS Correlation: -44.84 | EPS CAGR: -3.20% | SUE: 1.24 | # QB: 2
Revenue Correlation: -17.26 | Revenue CAGR: -0.55% | SUE: 1.52 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.92 | Chg30d=-0.05% | Revisions=+0% | Analysts=20
EPS current Year (2026-12-31): EPS=8.51 | Chg30d=-0.01% | Revisions=+25% | GrowthEPS=+9.1% | GrowthRev=+7.3%
EPS next Year (2027-12-31): EPS=9.30 | Chg30d=+0.04% | Revisions=+0% | GrowthEPS=+9.3% | GrowthRev=+8.1%
[Analyst] Revisions Ratio: +17% (up=2, down=1)